GET DAILY SIGNALSWhy Is ImmunityBio (IBRX) Stock Down -25.93% Today?
Key Takeaways
- IBRX shares tumbled roughly 25.9% — about $2.24 — to near $6.40 in morning trading Monday, after closing Friday at $8.64.
- The primary catalyst was a third-quarter earnings miss: revenue came in at $48.8 million versus a $59.2 million consensus, with a wider-than-expected loss of $0.18 per share.
- Dilution concerns compounded the decline, as investors weighed the company's recent $28.5 million at-the-market (ATM) stock offering against the revenue shortfall.
- The sell-off broke the stock decisively below its 200-day moving average for the first time since January and pushed shares toward their lowest levels in roughly nine months.
- Positive pipeline news — including a Phase 3 trial win for ANKTIVA plus BCG and a new Israeli approval — failed to offset the earnings disappointment.
- Explore Price Targets, Earnings, and Forecast pages for deeper data on this ticker.
- For AI-driven trade ideas across thousands of symbols, explore Trending AI Robots.
Opening Summary
ImmunityBio, Inc. (IBRX), a California-based commercial-stage immunotherapy company developing next-generation cancer and infectious-disease treatments built around its flagship therapy ANKTIVA, is under heavy selling pressure on Monday. After closing Friday's session at $8.64, IBRX shares plunged about 25.9% to roughly $6.40 in morning trading, with markets reacting to a disappointing third-quarter earnings report that overshadowed otherwise encouraging clinical and regulatory updates.
Earnings Results: A Revenue and Profit Miss
The dominant driver of the decline was the company's third-quarter financial results. ImmunityBio reported quarterly revenue of approximately $48.8 million, sharply below Wall Street's estimate of about $59.2 million — its first top-line miss in six quarters. The company also posted a net loss of $0.18 per share, considerably wider than the roughly $0.08-per-share loss analysts had modeled.
The company attributed the wider net loss partly to changes in the fair value of a related-party convertible note and warrant and derivative liabilities tied to the stock's prior appreciation, as well as higher research-and-development and general-and-administrative expenses. ImmunityBio ended September with about $334.3 million in cash, cash equivalents, and marketable securities.
Dilution Concerns Weigh on Sentiment
The revenue shortfall revived investor anxiety about further shareholder dilution. The company raised $28.5 million through an at-the-market (ATM) offering program during the quarter, and retail commentary pointed to dilution as a key risk if top-line growth continues to trail expectations. For a pre- and early-commercial biotech still funding a broad development pipeline, the combination of a revenue miss and ongoing capital needs gave traders a reason to reassess the stock's valuation.
Positive Pipeline News Fails to Stem the Slide
The earnings disappointment overshadowed two materially positive announcements. First, ImmunityBio said ANKTIVA combined with BCG met the primary goal of its Phase 3 QUILT-2.005 trial involving 370 patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC), showing a statistically significant improvement in treatment response versus BCG alone in patients with carcinoma in situ. The company plans to seek FDA approval for the expanded indication by year-end.
Second, the company announced approval of ANKTIVA plus BCG in Israel for BCG-unresponsive NMIBC with carcinoma in situ, extending the treatment's reach to 35 countries. While these developments underscore the franchise's long-term potential, they were not enough to counterbalance the near-term financial disappointment.
Market Context and Trading Activity
The move carried notable technical significance. IBRX traded decisively below its 200-day moving average, a threshold it had not breached since January, and sank toward its lowest levels in nearly nine months. The decline marked a sharp reversal from Friday's 7.8% advance, which had been fueled by earlier clinical momentum. Despite Monday's slump, the stock remains one of the year's stronger biotech performers, having surged more than 280% in 2026 on expanding ANKTIVA adoption and a string of regulatory milestones.
What Comes Next for IBRX
Investors will now focus on execution. Near-term watch items include the company's planned FDA filing for the expanded ANKTIVA indication by year-end, continued commercial uptake in newly approved markets, and whether revenue growth reaccelerates in subsequent quarters. The balance between pipeline progress and ongoing financing needs remains the central tension for the stock, and sentiment could stay fragile until the company demonstrates that its revenue trajectory can support its valuation without additional dilution.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of approaches to evaluate. Explore Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IBRX sees MACD Histogram just turned negative
IBRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 50 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for IBRX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 68 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IBRX as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.498). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is an Electronic Communication Network (ECN)?
What is a commodity swap?
What are the key advantages of a Backdoor Roth IRA?
What does the term "payroll" refer to, and could you provide a step-by-step explanation of how payroll taxes are calculated?
What does the term "trade signal" refer to, and how do traders analyze it?
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement